Analytical Considerations for High Sensitivity Troponin

Alan H.B. Wu, PhD, DABCC

Analytical Considerations for High Sensitivity Troponin


Q&A Archive


The newest generation of cardiac troponin I assays have significantly increased low-end analytical sensitivity, and researchers are learning more every day about how to use these highly sensitive assays clinically. How sensitive does your lab’s troponin assay need to be?

In an attempt to differentiate between these newer, more sensitive assays and traditional assays, terms like “high-sensitivity” and “ultrasensitive” are being used, causing confusion for both laboratorians and clinicians.

Dr. Wu’s presentation examines evidence of the superiority of troponin vs. CK-MB; compares cTnI and cTnT for risk stratification and diagnosing MI; outlines the performance of “next generation” troponin assays; offers lab requirements for serial testing and a definition of biological variability; and evaluates POCT for cardiac markers.





Alan H.B. Wu, PhD, DABCC, is Chief of Clinical Chemistry and Toxicology at San Francisco General Hospital and Professor of Laboratory Medicine, University of California, San Francisco. He received B.S. degrees in chemistry and biology from Purdue University, West Lafayette, Indiana, and a Ph.D. degree in analytical chemistry from the University of Illinois, Champaign-Urbana, Illinois. He completed a postdoctoral fellowship in clinical chemistry at Hartford Hospital. He is certified by the American Board of Clinical Chemistry in Clinical Chemistry and Toxicological Chemistry.

Dr. Wu’s research interest has been in the fields of biochemical markers for cardiovascular disease including CK-MB, myoglobin, troponin, B-type natriuretic peptide, markers of myocardial ischemia, and stroke. He has published more than 300 papers, abstracts, and book chapters in this field. He is author of Cardiac Markers, Totowa Press, 1st and 2nd edition (1999 and 2003). He is also a member of the National Academy of Clinical Biochemistry Laboratory Medicine Practice Guideline Committees on “Recommendations for the Use of Cardiac Markers in Coronary Artery Diseases.”

Dr. Wu has served on several editorial boards including Clinical Chemistry, Annals of Clinical Laboratory Science, Point of Care, and since 1998, he has served as co-editor-in-chief for Clinica Chimica Acta. He is a member of the AACC standardization subcommittees on CK-MB and cardiac troponin, and the International Federation of Clinical Chemistry Standardization of Markers of Cardiac Damage Committee.

Page Access: